The phrase "agent to progress" is correct and usable in written English.
It can be used to describe a person or entity that facilitates or drives advancement or improvement in a particular area.
Example: "The new policy serves as an agent to progress in our efforts to reduce carbon emissions."
Alternatives: "catalyst for advancement" or "driver of improvement."
This publication seek to assist agents of change to progress in this direction.
Yet the hierarchy, led by the technical director Michael Emenalo and the head of youth development, Neil Bath, have been at pains to stress the need for patience to youth players, as well as their parents and agents, as they seek to progress.
In conclusion, the pharmacokinetic and safety profile of OZ439 in both single and multiple dose studies in healthy subjects provides confidence to progress this agent to patient studies in the target population of acute uncomplicated malaria.
Although it is unlikely that all of the therapeutic agents currently under development will progress to approval for marketing, many show promise in clinical trials and will hopefully continue to progress along the approval process.
Considering the DSLO levels rather than the course grades level allows the Academic Advisor Agent to: (i) assess the progress achieved by the deaf student at the end of every period, (ii) identify any learning obstacles at an early stage, and (iii) continuously propose learning activities and learning targets that are more fitting to the learner weaknesses.
Results from three of these studies using different dosing schedules have been reported [ 13– 15] and the agent has progressed to human Phase II clinical trials.
To date, four agents have progressed to the market with two, temozolomide (I Temodal®) and 4-hydroxyandrostenedione (II Lentaron®), being particularly successful and many more showing promising activity in Phase I, II and III trials.
In light of these activities, XIAP inhibition through small molecules or antisense has received considerable pharmaceutical industry focus, and multiple agents have progressed to clinical trials [ 3].
Of the 30 agents that have progressed to clinical evaluation beyond a Phase I trial, 11 are currently undergoing or are scheduled for Phase II studies.
Of the BRAF-targeted agents, Sorafenib has progressed to approval by the United States Food and Drug Administration for therapy of renal cell carcinoma and is under evaluation for melanoma, thyroid cancer and other malignancies.
